Neuroblastoma is one of the most common solid tumors of childhood. Over half of the high risk patents relapse and the mortality rate is high with multimodal therapy.
Introduction
Neuroblastoma is the most common extracranial solid tumor in childhood (1) . It is remarkable for its clinical range, encompassing spontaneous regression to progression and death. Approximately 12% of pediatric deaths from malignancy are due to neuroblastoma. The high-risk phenotype is generally characterized by disseminated disease and increased mortality (2, 3) . Additional features associated with the high-risk phenotype include histopathological features and MYCN amplification (2, 4) . In these high-risk patients, more than half of the patients relapse after multimodal therapy.
Recently, anti-GD2 immunotherapy to treat minimal residual disease after achieving remission has led to additional improvements in survival, however, stem cell transplantation is considered standard-of-care currently for high-risk patients (5, 6 ).
Autologous stem cell transplantation for neuroblastoma has been under investigation for over 20 years and in 1997, a large retrospective analysis found improved survival in patients treated with stem cell transplant as opposed to conventional chemotherapy (7) . The single largest randomized trial of autologous stem cell transplantation was the Children's Cancer Group 3891 study (8) . In this study, all patients received a consolidation regimen and then were randomized to autologous transplantation or additional chemotherapy. The study established autologous transplantation and isotretinoin therapy as the standard-of-care for high-risk patients. In spite of this, more than half of the patients relapsed. In recent years, the autologous stem cell transplantation concept has been extended to sequential cycles. A tandem transplant allows for greater dose intensity and has shown promise as a strategy to improve outcomes with the largest study demonstrating a 3-year event-free survival of 55% (9) (10) (11) .
One of the significant issues in patients who receive a tandem stem cell transplant is prolonged immune suppression. Post-transplant lymphoproliferative disease and other viral morbidities can occur (12) (13) . This suggests that there is prolonged, medically significant immune suppression in this population. To mitigate immune suppression in other settings, autologous expanded T cells have been utilized to provide defense against viral infections (14) (15) (16) (17) (18) . We examined immunologic reconstitution in a cohort of children with high risk neuroblastoma who received a tandem transplant and were then randomized to receive either an autologous expanded T cell product on Day 2 or Day 90. We carefully characterized immunologic parameters as well as their ability to respond to vaccines. The subjects that received the early autologous T cell product had superior T cell reconstitution and oligoclonality was suppressed during the vulnerable window post-transplant. Significant responses to vaccines were seen almost exclusively in subjects who received the early autologous T cell product.
Research. 
Methods

Study Design
This study protocol was approved by the Institutional Review Boards at Children's Hospital of Philadelphia and Boston Children's and informed consent was obtained from all participants. The trial was preregistered at ClinicalTrials.gov as NCT00017368. The analysis plan was determined before study initiation and laboratory assays were performed in a blinded fashion. In an initial (pilot) safety and feasibility phase, patients received autologous expanded T cells on Day 2 (Early), Day 12 (Middle), or Day 90 (Late) after the second stem cell infusion. In a second phase of the study, patients were randomized after enrollment to either the Early (Day 2) or Late the Day 90 group, as assigned. In the analysis of the second, randomized phase, 22 patients were randomized and included in the immune response analysis, including vaccine response.
T cell Infusions
Patients underwent a single 2-6 blood volume leukapheresis at diagnosis (prior to receiving chemotherapy) to collect peripheral blood mononuclear cells (PBMC). The cells were depleted of monocytes and cryopreserved. The T cells underwent an established GMP co-stimulated activation and expansion protocol using CD3-and CD28-linked beads (19) . All infused T cell products were required to meet FDAspecified safety and release criteria prior to infusion. The target number of T cells for infusion was 2-8 x10 T cell proliferation, T cell repertoire, T cell ELISPOTs and B cell ELISPOTs were performed as previously described (18) . The assessment of influenza and pneumococcal vaccine responses utilized a standard hemagglutination inhibition (HAI) assay optimized for the vaccine administered each year and a commercial laboratory for pneumococcal responses (21) . Next generation sequencing was performed by Adaptive TCR technologies (www.immunoseq.com) using DNA from PBMC, TCRβ-specific primers, and a deep level of sequencing on the Illumina platform (22) .
Statistical analysis
Research. The linear regression model was utilized for analyzing repeated measures based on the Generalized Estimating Equation (GEE) method using SAS GENMOD. The regression models included Group effects, Time effects, and the interaction of Group*Time. Baseline differences were examined to exclude group differences related to randomization. To define the cumulative differences between the two groups, the area under the curve was calculated. The independent t-test, Kruskal-Wallis test, or the Mann-Whitney test were used for the comparisons of single time points. The small size of the patients and the severity of their illness occasionally prevented obtaining all study samples. Each analysis indicates the number of subjects included. The studies reported were pre-defined in the study design. Significance was set at p<0.05. Data analysis was performed by Drs. Sullivan, Grupp, Boyer, Luning Prak and Jawad. All authors had access to study data. 
Results
Patient characteristics
All patients had high-risk neuroblastoma and were over one year of age. All but two patients had stage 4 disease. Consistent with the known epidemiology of the disease, the children ranged in age from 1-5 years of age. The subjects were roughly half female and the majority of patients were Caucasian. For the pilot study of T cell This study was not designed or powered to look at the impact of T cell infusion on survival. However, we performed a descriptive analysis of event-free survival (EFS) in the cohort and among patients assigned to day 12, day 2 and day 90 T cell infusion.
Five year EFS in the cohort was 55%, which was similar to our prior report of 47% (12) .
No differences between T cell infusion subgroups were apparent, with 5 year EFS in the day 2, 12, and 90 subgroups being 55%, 50%, and 58%, respectively. One subject in 
Pilot study of T cell reconstitution, comparing three time points
We hypothesized that autologous, co-stimulated expanded T cells would alter the composition of the T cell compartment significantly. This CD3/CD28 bead-stimulated GMP cell therapy product has been previously demonstrated to produce CD4/CD8
ratios of approximately 1:1, and to maintain the T cell receptor repertoire of the input T cells (14, 15, 23) . For analysis of the initial pilot phase, clinical measurements of ALC, CD3, CD4, and CD8 counts were used. These data are shown in Figure 2 and demonstrate a profound impact of T cell infusion on the T cell count. The group receiving T cells at Day 2 had improved CD4 and CD8 T cell counts compared to the Day 90 Group in the Day 2-90 interval. Interestingly, the Day 2 Group also had improved T cell recovery compared to the Day 12 Group, suggesting that very early T cell infusion might result in even more robust CD4 cell recovery. A similar effect across the groups was seen in terms of CD8+ cell recovery.
T cell recovery after early or late T cell infusions
During the randomized phase of the study, we expanded the immunologic reconstitution assessments. We first characterized the T cells in the expanded autologous T cell product because there have been no previous studies of pediatric specimens. We identified the frequency of stem-like T cells (24) , follicular helper T cells, regulatory T cells and other subsets of biological relevance. Surprisingly, there were almost no differences between the cell populations in the expanded products from children and adults, although naïve CD4 T cells were increased in the expanded product from the children compared to adults (Supplemental Data 1). Based on data from non-human primates, it is estimated that a typical 2-3 year old child has a total body content of approximately 2x10 11 T cells (25) . Therefore, the increase in T cell count in the peripheral blood was unlikely to be directly due to the addition of 2-8 x10 To examine proliferative responses after stimulation, we incubated PBMC with PHA. CFSE dilution was defined using flow cytometry and the Proliferation Index (a measure of average number of cell divisions a responding cell has undergone) and the Percent Divided (a measure of the fraction of cells competent to divide) were calculated.
The Proliferation Index was higher in the Early Group but this difference did not reach statistical significance (p=0.0522), however, the Percent Divided after PHA was significantly higher in the Early Group compared to the Late Group at day 60 with p=0.0232 ( Figure 4C ). Therefore, provision of an autologous T cell product at an early Expansion of T cells could be associated with contraction of the T cell repertoire.
We initially analyzed the diversity of the repertoire by spectratyping (29). Unexpectedly, the diversity was impressively restricted in the patients prior to any chemotherapy with over half of the Vβ families missing or having oligoclonal peaks ( Figure 5) . A previous study of adults, using this technology, found approximately 10% abnormal Vβ families (30) . There was a modest increase in the frequency of abnormal Vβ families at days 30 and 60 in the Late Group, suggesting expansion of a small number of founder clones.
To better explore the contribution of the infusion to the T cell repertoire, five patients in the Early Group and four patients in the Late Group were examined using next generation sequencing to better identify alterations to the repertoire. We hypothesized that baseline repertoire contraction could be due to expansion of a tumor-specific clone, however, at baseline, there were no T cell receptor (TCR) sequences shared by all patients. For all four patients who had baseline samples available, the number of unique reads was higher in the infusion sample compare to the baseline sample, supporting the previous finding that in vitro expansion using this method preserves polyclonality (15) .
There were relatively few clones from the infusion that appeared in later time points, < 5.5% in all cases. This is consistent with the small contribution expected from the infusion. Unexpectedly, provision of this small number of cells led to increased repertoire diversity (diminished oligoclonality) ( Figure 5 ). For this analysis, we enumerated the number of clones comprising over 5% of the total reads as a marker of oligoclonality. There were no oligoclonal sequences at baseline, but at Day 30, the Late Group had an average of 4 oligoclonal sequences whereas the Early Group had an average of 0.25 oligoclonal TCR sequences (p=NS). Similarly, when the frequencies of the most common clones were analyzed, the Early Group had a mean frequency of 3.5% while the Late Group had a mean frequency of 13.5% (p=NS). As a final measure of diversity, we enumerated the number of distinct Vβ-J combinations at each time point. The Early Group had significantly more diversity at Day 30 compared to the Late Group (p=0.008, Figure 5 ).
The suppression of oligoclonality could be due to greater "fitness" of the ex vivo expanded cells or could be due to enhancement of thymic output, such as has been previously suggested (31) To explore this, we performed analyses of T cell receptor excision circles (TRECs).
Four of nine subjects in the Early Group had increased TRECs at day 30 compared to their baseline, while 1/7 of the Late Group did. At day 150, 5/7 of the Late Group and 2/6 of the Early Group had increased TRECs compared to baseline. in the inactivated vaccine. There was wide variability in the Early Group while the Late Group exhibited very little variability. There were no significant differences in the mean titer between the two groups and overall the responses were extremely low. We also calculated the seroconversion frequency at each time point by defining a four-fold increase from the baseline titer. Two patients in the Early Group (n=14) produced a four-fold titer increase after vaccination to all three serotypes. Three additional patients produced a four-fold increase in titer to at least one serotype in the Early Group. In contrast, only one patient in the Late Group (n=8) produced a four-fold response to a single serotype (p value not significant). The low titers at baseline suggest that this population was largely naïve to influenza, which may have compromised their ability to respond to the vaccine. We therefore examined responses to the conjugated pneumococcal vaccine, which the patients should have received as part of their child care prior to developing neuroblastoma.
Responses to vaccines
Pneumococcal responses were evaluated as representative of an antigen previously encountered and a typical memory response ( Figure 6 ). Fourteen serotypes were evaluated: seven contained in the conjugate vaccine and seven serotypes not in the vaccine. There were no responses to the serotypes that are not in the vaccine, as expected. For the serotypes in the vaccine, the baseline titers were higher than the non-vaccine serotypes, consistent with prior vaccination. There was a dichotomous response at the one year time point with the Early Group having significantly higher responses than the Late Group at one year. To determine whether this effect was due to a single serotype, the serotypes were individually evaluated. All serotypes individually were significantly higher at one year in the Early Group compared to the Late Group and all patients exhibited the same pattern. These data support the beneficial effect of the autologous T cell product on host humoral memory responses.
B cell maturation
To better understand how the early autologous T cell infusion led to greater antibody production, we examined the B cell subsets in the peripheral blood at baseline and various time points after transplantation. Neither total B cells nor any of the subsets differed between the Early and Late Groups although B cell maturation appeared to be modestly accelerated in the Early Group (Supplemental Data 3). To examine B cell function, we utilized B cell ELISPOTs, measuring both the total IgG and the influenzaspecific IgG produced. There were no differences between the Early Group and the Late Group but responses were universally low using this assay (data not shown).
Discussion
This study was designed to test the efficacy of an adoptive transfer of a costimulated, activated autologous T cell product as an approach to regenerate cellular immunity after high dose cytotoxic therapy. Patients who receive a tandem transplant for high-risk neuroblastoma are rendered severely immune deficient for a prolonged period of time (5, 9, 13, 32, 33) . Consequences of the immune compromise are viral morbidity and mortality related to infection (13) . The provision of an autologous T cell product can provide support during the vulnerable post-transplant period. In adults, autologous T cell products have been utilized with a significant improvement in immunologic function as measured by T cell counts and vaccine responses (18, (34) (35) (36) (37) . is associated with conversion to a memory phenotype and we hypothesize that both thymic production and homeostatic expansion contributed to quantitative reconstitution (39) (40) (41) . The TREC data were not uniform among subjects but the data were suggestive of the induction of thymopoiesis in some patients after the T cell infusion.
Overall, the Early (Day 2) T cell infusions resulted in superior T cell reconstitution as assessed by quantitative and qualitative measures and we believe this will improve the defense against opportunistic infections.
To probe the breadth of improvement in immunologic function, we vaccinated children after their second transplant. We anticipated that most children would be naïve to influenza because of their young age and that nearly all children would have had the conjugated pneumococcal vaccine as part of routine childcare. We noted that the baseline aggregate titers to pneumococcal serotypes were significantly different between the vaccine serotypes and the non-vaccine serotypes, confirming that this cohort was previously vaccinated. There was a modest increase in titers at the Day 30 time point but the most remarkable result was the dramatic increase in vaccine-specific pneumococcal titers at the one-year time point, indicating that long term B cell immunity is dependent on antigen-specific T cell function.
The delayed kinetics were surprising, however, similar studies in adults demonstrated that priming prior to the T cell harvest markedly improves subsequent vaccine responses (18, 19) . In those studies, the conditioning regimen did not deplete Harnessing the immune system for an anti-tumor effect is a long-term goal of immune reconstitution and infusion of genetically modified T cells expanded using CD3-and CD28-linked beads recently demonstrated dramatic anti-tumor responses (26, 27) .
The current data suggest that priming is important and a study of adults receiving a similar product also concluded that priming optimized vaccine responses (35) . The most important lesson is that the autologous T cell product can provide important immunological support but it must be administered early. These results are also the first indication that the kinetics of immune reconstitution in the pediatric immune system has profound effects on long-term humoral immunity. These results may guide future studies to reconstitute immunity after high dose chemotherapy and perhaps for the induction of anti-tumor immunity. by PCR analysis (spectratyping). There were no differences between the Early Group and the Late Group, however, the baseline diversity was poor. B) To assess oligoclonality, next generation sequencing was used. As a measure of oligoclonality, the number of clones that represented at least 5% of the reads were enumerated. The infused product itself was polyclonal and oligoclonality in the Late Group seen at day 30 was corrected after infusion at day 90. C) The frequency of the most abundant clone was also assessed as a measure of oligoclonality. The Late Group has a higher mean 
